Cargando…

Late hepatitis C virus diagnosis among patients with newly diagnosed hepatocellular carcinoma: a case–control study

BACKGROUND: New direct-acting antiviral therapies have revolutionized hepatitis C virus (HCV) infection therapy. Nonetheless, once liver cirrhosis is established, the risk of hepatocellular carcinoma (HCC) still exists despite virus eradication. Late HCV diagnosis hinders timely access to HCV treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Shen-Shong, Hu, Hsiao-Yun, Chen, Yu-Chin, Yen, Yung-Feng, Huang, Nicole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482748/
https://www.ncbi.nlm.nih.gov/pubmed/36115934
http://dx.doi.org/10.1186/s12876-022-02504-6
_version_ 1784791522872393728
author Chang, Shen-Shong
Hu, Hsiao-Yun
Chen, Yu-Chin
Yen, Yung-Feng
Huang, Nicole
author_facet Chang, Shen-Shong
Hu, Hsiao-Yun
Chen, Yu-Chin
Yen, Yung-Feng
Huang, Nicole
author_sort Chang, Shen-Shong
collection PubMed
description BACKGROUND: New direct-acting antiviral therapies have revolutionized hepatitis C virus (HCV) infection therapy. Nonetheless, once liver cirrhosis is established, the risk of hepatocellular carcinoma (HCC) still exists despite virus eradication. Late HCV diagnosis hinders timely access to HCV treatment. Thus, we determined trends and risk factors associated with late HCV among patients with a diagnosis of HCC in Taiwan. METHODS: We conducted a population-based unmatched case–control study. 2008–2018 Claims data were derived from the Taiwan National Health Insurance Research Database. Individuals with an initial occurrence of liver cancer between 2012 and 2018 were included. The late HCV group were referred as individuals who were diagnosed with HCC within 3 years after HCV diagnosis. The control group were referred as individuals who were diagnosed more than 3 years after the index date. We used multivariable logistic models to explore individual- and provider-level risk factors associated with a late HCV diagnosis. RESULTS: A decreasing trend was observed in the prevalence of late HCV-related HCC diagnosis between 2012 and 2018 in Taiwan. On an individual level, male, elderly patients, patients with diabetes mellitus (DM), and patients with alcohol-related disease had significantly higher risks of late HCV-related HCC diagnosis. On a provider level, patients who were mainly cared for by male physicians, internists and family medicine physicians had a significantly lower risk of late diagnosis. CONCLUSIONS: Elderly and patients who have DM and alcohol related disease should receive early HCV screening. In addition to comorbidities, physician factors also matter. HCV screening strategies shall take these higher risk patients and physician factors into consideration to avoid missing opportunities for early intervention. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12876-022-02504-6.
format Online
Article
Text
id pubmed-9482748
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94827482022-09-19 Late hepatitis C virus diagnosis among patients with newly diagnosed hepatocellular carcinoma: a case–control study Chang, Shen-Shong Hu, Hsiao-Yun Chen, Yu-Chin Yen, Yung-Feng Huang, Nicole BMC Gastroenterol Research BACKGROUND: New direct-acting antiviral therapies have revolutionized hepatitis C virus (HCV) infection therapy. Nonetheless, once liver cirrhosis is established, the risk of hepatocellular carcinoma (HCC) still exists despite virus eradication. Late HCV diagnosis hinders timely access to HCV treatment. Thus, we determined trends and risk factors associated with late HCV among patients with a diagnosis of HCC in Taiwan. METHODS: We conducted a population-based unmatched case–control study. 2008–2018 Claims data were derived from the Taiwan National Health Insurance Research Database. Individuals with an initial occurrence of liver cancer between 2012 and 2018 were included. The late HCV group were referred as individuals who were diagnosed with HCC within 3 years after HCV diagnosis. The control group were referred as individuals who were diagnosed more than 3 years after the index date. We used multivariable logistic models to explore individual- and provider-level risk factors associated with a late HCV diagnosis. RESULTS: A decreasing trend was observed in the prevalence of late HCV-related HCC diagnosis between 2012 and 2018 in Taiwan. On an individual level, male, elderly patients, patients with diabetes mellitus (DM), and patients with alcohol-related disease had significantly higher risks of late HCV-related HCC diagnosis. On a provider level, patients who were mainly cared for by male physicians, internists and family medicine physicians had a significantly lower risk of late diagnosis. CONCLUSIONS: Elderly and patients who have DM and alcohol related disease should receive early HCV screening. In addition to comorbidities, physician factors also matter. HCV screening strategies shall take these higher risk patients and physician factors into consideration to avoid missing opportunities for early intervention. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12876-022-02504-6. BioMed Central 2022-09-17 /pmc/articles/PMC9482748/ /pubmed/36115934 http://dx.doi.org/10.1186/s12876-022-02504-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Chang, Shen-Shong
Hu, Hsiao-Yun
Chen, Yu-Chin
Yen, Yung-Feng
Huang, Nicole
Late hepatitis C virus diagnosis among patients with newly diagnosed hepatocellular carcinoma: a case–control study
title Late hepatitis C virus diagnosis among patients with newly diagnosed hepatocellular carcinoma: a case–control study
title_full Late hepatitis C virus diagnosis among patients with newly diagnosed hepatocellular carcinoma: a case–control study
title_fullStr Late hepatitis C virus diagnosis among patients with newly diagnosed hepatocellular carcinoma: a case–control study
title_full_unstemmed Late hepatitis C virus diagnosis among patients with newly diagnosed hepatocellular carcinoma: a case–control study
title_short Late hepatitis C virus diagnosis among patients with newly diagnosed hepatocellular carcinoma: a case–control study
title_sort late hepatitis c virus diagnosis among patients with newly diagnosed hepatocellular carcinoma: a case–control study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482748/
https://www.ncbi.nlm.nih.gov/pubmed/36115934
http://dx.doi.org/10.1186/s12876-022-02504-6
work_keys_str_mv AT changshenshong latehepatitiscvirusdiagnosisamongpatientswithnewlydiagnosedhepatocellularcarcinomaacasecontrolstudy
AT huhsiaoyun latehepatitiscvirusdiagnosisamongpatientswithnewlydiagnosedhepatocellularcarcinomaacasecontrolstudy
AT chenyuchin latehepatitiscvirusdiagnosisamongpatientswithnewlydiagnosedhepatocellularcarcinomaacasecontrolstudy
AT yenyungfeng latehepatitiscvirusdiagnosisamongpatientswithnewlydiagnosedhepatocellularcarcinomaacasecontrolstudy
AT huangnicole latehepatitiscvirusdiagnosisamongpatientswithnewlydiagnosedhepatocellularcarcinomaacasecontrolstudy